Anna Schmitt

1.9k total citations
20 papers, 313 citations indexed

About

Anna Schmitt is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Anna Schmitt has authored 20 papers receiving a total of 313 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 8 papers in Hematology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Anna Schmitt's work include Chronic Lymphocytic Leukemia Research (7 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Lymphoma Diagnosis and Treatment (6 papers). Anna Schmitt is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Lymphoma Diagnosis and Treatment (6 papers). Anna Schmitt collaborates with scholars based in France, Canada and United States. Anna Schmitt's co-authors include Nöel Milpied, Pierre Soubeyran, Barbara Petit, Manuel Devesa, Marie Parrens, Jean‐Philippe Merlio, Isabelle Soubeyran, Jean Feuillard, Nathalie Gachard and David Rizzo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Medical Internet Research.

In The Last Decade

Anna Schmitt

18 papers receiving 305 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Schmitt France	7	216	172	96	63	60	20	313
M. Angelopoulou Greece	6	218 1.0×	196 1.1×	53 0.6×	73 1.2×	84 1.4×	8	292
Alessandra Trojani Italy	8	257 1.2×	227 1.3×	74 0.8×	52 0.8×	134 2.2×	17	373
Roshanak Bob Germany	6	135 0.6×	165 1.0×	62 0.6×	128 2.0×	37 0.6×	8	259
Jackline de Paula Ayres-Silva Brazil	7	145 0.7×	173 1.0×	40 0.4×	48 0.8×	42 0.7×	13	291
Marc Heizmann Switzerland	7	157 0.7×	273 1.6×	69 0.7×	138 2.2×	29 0.5×	9	358
S. Mellou Greece	8	89 0.4×	41 0.2×	100 1.0×	85 1.3×	53 0.9×	12	298
Julien Broséus France	9	152 0.7×	32 0.2×	136 1.4×	40 0.6×	21 0.3×	23	300
Alessandra Cuttica Italy	8	80 0.4×	204 1.2×	87 0.9×	147 2.3×	41 0.7×	10	287
Willem Kraan Netherlands	6	117 0.5×	201 1.2×	23 0.2×	93 1.5×	36 0.6×	8	276
Stacey Kalambakas United States	9	136 0.6×	40 0.2×	69 0.7×	60 1.0×	11 0.2×	17	295

Countries citing papers authored by Anna Schmitt

Since Specialization

Citations

This map shows the geographic impact of Anna Schmitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Schmitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Schmitt more than expected).

Fields of papers citing papers by Anna Schmitt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Schmitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Schmitt. The network helps show where Anna Schmitt may publish in the future.

Co-authorship network of co-authors of Anna Schmitt

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Schmitt. A scholar is included among the top collaborators of Anna Schmitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Schmitt. Anna Schmitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ahle, Guido, Émeline Tabouret, Roch Houot, et al.. (2024). Primary central nervous system lymphoma of the spinal cord: A LOC network cohort study. Revue Neurologique. 181(3). 200–209.

Dû, Katell Le, Anne-Lise Septans, Anna Schmitt, et al.. (2023). A New Option for Pain Prevention Using a Therapeutic Virtual Reality Solution for Bone Marrow Biopsy (REVEH Trial): Open-Label, Randomized, Multicenter, Phase 3 Study. Journal of Medical Internet Research. 25. e38619–e38619. 6 indexed citations

Dufour, Jean‐François, Sylvain Choquet, Khê Hoang‐Xuan, et al.. (2023). Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study. Annals of Hematology. 102(5). 1159–1169. 2 indexed citations

Dû, Katell Le, Anne-Lise Septans, Frédéric Maloisel, et al.. (2021). A new option in pain prevention with bliss, a therapeutic virtual reality solution in bone marrow biopsy context: Results of a French open-label multicenter randomized phase II/III study (REVEH Trial).. Journal of Clinical Oncology. 39(15_suppl). 6573–6573.

Étienne, Gabriel, Stéphanie Dulucq, C. Fabères, et al.. (2020). A single center evaluation of cost savings related to treatment‐free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco‐economy larger study. British Journal of Haematology. 189(3). e97–e100. 2 indexed citations

Étienne, Gabriel, Stéphanie Dulucq, Françoise Huguet, et al.. (2019). Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors. Cancer Medicine. 8(11). 5173–5182. 15 indexed citations

Lesueur, Paul, Gandhi Damaj, Khê Hoang‐Xuan, et al.. (2019). P14.73 Toxicity and outcomes of reduced-dose whole brain radiotherapy as consolidation treatment for patients with CNS lymphoma in real life setting. Neuro-Oncology. 21(Supplement_3). iii84–iii85. 1 indexed citations

Nicolini, Franck E., Vincent Alcazer, Pascale Cony‐Makhoul, et al.. (2018). Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib. Experimental Hematology. 64. 97–105.e4. 6 indexed citations

Houillier, Caroline, Guido Ahle, Olivier Chinot, et al.. (2018). (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study. Annals of Hematology. 98(4). 915–922. 6 indexed citations

10.

Ribrag, Vincent, Franck Morschhauser, Pam McKay, et al.. (2018). Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 132(Supplement 1). 4196–4196. 15 indexed citations

11.

Ghesquières, Hervé, Caroline Houillier, Olivier Chinot, et al.. (2016). Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network. Blood. 128(22). 785–785. 30 indexed citations

12.

Ribrag, Vincent, Jean‐Charles Soria, Jean‐Marie Michot, et al.. (2015). Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients. Blood. 126(23). 473–473. 33 indexed citations

13.

Étienne, Gabriel, Stéphanie Dulucq, Anna Schmitt, et al.. (2014). ELN 2013 response status criteria: Relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?. American Journal of Hematology. 90(1). 37–41. 6 indexed citations

14.

Étienne, Gabriel, Stéphanie Dulucq, Franck E. Nicolini, et al.. (2013). Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica. 99(3). 458–464. 40 indexed citations

15.

Gachard, Nathalie, Marie Parrens, Isabelle Soubeyran, et al.. (2012). IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia. 27(1). 183–189. 120 indexed citations

16.

Étienne, Gabriel, Stéphanie Dulucq, Anna Schmitt, et al.. (2012). Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy. Blood. 120(21). 3754–3754. 6 indexed citations

17.

Vigouroux, Stéphane, Reza Tabrizi, Xavier Lafarge, et al.. (2010). Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors. Biology of Blood and Marrow Transplantation. 17(1). 93–100. 2 indexed citations

18.

Dromer, Claire, Reza Tabrizi, Stéphane Vigouroux, et al.. (2010). Bronchiolitis Obliterans After Allogeneic Stem Cell Transplantation: a Single Center Retrospective Study of Risk Factors.. Blood. 116(21). 4507–4507. 1 indexed citations

19.

Leguay, Thibaut, Arnaud Pigneux, Reza Tabrizi, et al.. (2010). Allograft After Pediatric-Inspired Therapy Does Not Improve Young patient's Outcome with High Risk Philadelphia- Chromosome-Negative Acute Lymphoblastic Leukemia (Ph-ALL). A Single Center Report. Blood. 116(21). 3528–3528. 2 indexed citations

20.

Donnet, Anne, Anna Schmitt, Henry Dufour, & F. Grisoli. (1999). Neuropsychological Follow-up of Twenty Two Adult Patients After Surgery for Craniopharyngioma. Acta Neurochirurgica. 141(10). 1049–1054. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact